Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025259 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,734
- Enrollment target
NCT00025259: Completed Phase 3 study, sponsored by Children's Oncology Group.
NCT00025259 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 1,734 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (125% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025259, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,734 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
Primary Outcome
Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Dexamethasone
- BIOLOGICAL Bleomycin Sulfate
- DRUG Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,734 participants |
| Start Date | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00025259 record still lists
NCT00025259 is an interventional study that assigns participants to a tested intervention. Its 1,734 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (125% higher).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00025259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025259 about?
NCT00025259 is a clinical study titled "Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease". This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop...
What is the current status of trial NCT00025259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,734 participants. The study started on 2002-09.
What interventions are being tested in trial NCT00025259?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Bleomycin Sulfate (BIOLOGICAL), Cytarabine (DRUG).
Who is sponsoring clinical trial NCT00025259?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00025259's enrollment target sits among peer trials
1,734 130th of 2000 higher than 1,871 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia